BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 26660518)

  • 1. The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.
    Phan-Lai V; Dang Y; Gad E; Childs J; Disis ML
    Clin Cancer Res; 2016 May; 22(9):2207-16. PubMed ID: 26660518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice.
    Wang B; Zaidi N; He LZ; Zhang L; Kuroiwa JM; Keler T; Steinman RM
    Breast Cancer Res; 2012 Mar; 14(2):R39. PubMed ID: 22397502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells.
    Gritzapis AD; Voutsas IF; Lekka E; Papamichail M; Baxevanis CN
    Cancer Res; 2010 Apr; 70(7):2686-96. PubMed ID: 20233867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expansion of HER2/neu-specific T cells ex vivo following immunization with a HER2/neu peptide-based vaccine.
    Knutson KL; Disis ML
    Clin Breast Cancer; 2001 Apr; 2(1):73-9. PubMed ID: 11899386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
    Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
    Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNFα Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma.
    Tähtinen S; Blattner C; Vähä-Koskela M; Saha D; Siurala M; Parviainen S; Utikal J; Kanerva A; Umansky V; Hemminki A
    J Immunother; 2016; 39(9):343-354. PubMed ID: 27741089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
    Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC
    Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4(+) T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8(+) T-cell Targeting of HER2/neu-Expressing Cancers.
    Datta J; Xu S; Rosemblit C; Smith JB; Cintolo JA; Powell DJ; Czerniecki BJ
    Cancer Immunol Res; 2015 May; 3(5):455-63. PubMed ID: 25791067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
    Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
    Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
    Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
    Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.
    Cecil DL; Holt GE; Park KH; Gad E; Rastetter L; Childs J; Higgins D; Disis ML
    Cancer Res; 2014 May; 74(10):2710-8. PubMed ID: 24778415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells.
    Morales JK; Kmieciak M; Graham L; Feldmesser M; Bear HD; Manjili MH
    Cancer Immunol Immunother; 2009 Jun; 58(6):941-53. PubMed ID: 18979098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
    Dang Y; Knutson KL; Goodell V; dela Rosa C; Salazar LG; Higgins D; Childs J; Disis ML
    Clin Cancer Res; 2007 Mar; 13(6):1883-91. PubMed ID: 17363545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cells expressing ErbB-2/neu elicit protective antibreast tumor immunity in vivo, which is paradoxically suppressed by IFN-gamma and tumor necrosis factor-alpha priming.
    Romieu-Mourez R; François M; Abate A; Boivin MN; Birman E; Bailey D; Bramson JL; Forner K; Young YK; Medin JA; Galipeau J
    Cancer Res; 2010 Oct; 70(20):7742-7. PubMed ID: 20924101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-GD2 Antibodies Conjugated to IL15 and IL21 Mediate Potent Antitumor Cytotoxicity against Neuroblastoma.
    Nguyen R; Zhang X; Sun M; Abbas S; Seibert C; Kelly MC; Shern JF; Thiele CJ
    Clin Cancer Res; 2022 Sep; 28(17):3785-3796. PubMed ID: 35802683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Lymphodepletion Is Insufficient to Replace Exogenous IL2 or IL15 Therapy in Augmenting the Efficacy of Adoptively Transferred Effector CD8
    Johnson CB; May BR; Riesenberg BP; Suriano S; Mehrotra S; Garrett-Mayer E; Salem ML; Jeng EK; Wong HC; Paulos CM; Wrangle JM; Cole DJ; Rubinstein MP
    Cancer Res; 2018 Jun; 78(11):3067-3074. PubMed ID: 29636345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
    Slaney CY; von Scheidt B; Davenport AJ; Beavis PA; Westwood JA; Mardiana S; Tscharke DC; Ellis S; Prince HM; Trapani JA; Johnstone RW; Smyth MJ; Teng MW; Ali A; Yu Z; Rosenberg SA; Restifo NP; Neeson P; Darcy PK; Kershaw MH
    Clin Cancer Res; 2017 May; 23(10):2478-2490. PubMed ID: 27965307
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3-CD8+ T cells.
    Deng S; Sun Z; Qiao J; Liang Y; Liu L; Dong C; Shen A; Wang Y; Tang H; Fu YX; Peng H
    JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
    Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
    Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.